메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Renalys Announces Completion of Primary Endpoint Data Col…

TOKYO, Oct. 10, 2025 -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (development code: RE-021) for IgA nephropathy in Japan. The primary endpoint evaluated was the urine protein creatinine ratio (24-hour urine collection) at 36 weeks and data have now been collected for all eligible patients. Renalys will proceed with analyses of efficacy and safety through 36 weeks of treatment, as well as comparisons with global Phase III trial resu
- 김갑성 기자
- 2025-10-10 14:00
IHH Healthcare launches Global Incubator to fuel game-cha…

[ 메디채널 김갑성 기자 ] By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthcare ecosystem. "Through this Global Incubator Programme, we are expanding our innovation drive to support early-stage healthcare innovators, empowering them to develop solutions that can transform patient care. At IHH Healthcare, we catalyse next-level care through meaningful innovation, strategic partnerships and powerful synergies. By providing access to our extensive network, clinical expertise, and resourc
- 김갑성 기자
- 2025-10-10 13:09
ACROBiosystems and Partners Conclude OrganoAsia 2025

Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization SEOUL, South Korea, Oct. 10, 2025 -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for org
- 김갑성 기자
- 2025-10-10 09:32
ACROBiosystems and Partners Conclude OrganoAsia 2025

- Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for organoid technol
- 김갑성 기자
- 2025-10-10 09:21
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consec…

SHANGHAI, Oct. 10, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This top-tier rating by MSCI, a premier global data provider of ESG ratings and research, places WuXi Biologics among an elite group of companies globally recognized for outstanding ESG performance, and acknowledges the company's strong leadership in advocating sustainability, particularly in the key areas of clim
- 김갑성 기자
- 2025-10-10 08:30
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercep…

EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON, South Korea, Oct. 10, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
- 김갑성 기자
- 2025-10-10 06:56
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 As…

[ 메디채널 김갑성 기자 ] New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer's disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex s
- 김갑성 기자
- 2025-10-10 05:23
POMDOCTOR LIMITED Announces Closing of Initial Public Offerin…

GUANGZHOU, China, Oct. 10, 2025 -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs began trading on Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM." The Co
- 김갑성 기자
- 2025-10-10 04:05
Lifespan-Backed Algen Biotechnologies Partners with Astra…

NORWALK, Conn., Oct. 9, 2025 -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology. The partnership will combine Algen's cutting-edge functional genomics and machine learning platform with AstraZeneca's deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of n
- 김갑성 기자
- 2025-10-09 23:09
Kimberly-Clark Launches Enhanced Global Partnerships to…

DALLAS, Oct. 9, 2025 -- Kimberly-Clark Corporation (NASDAQ: KMB) is deepening its commitment to advancing essential care for women and girls through four enhanced strategic, charitable partnerships. Through new programs with Baby2Baby, Plan International, Project HOPE, and UNICEF, Kimberly-Clark aims to expand access to life-changing care in Brazil, Peru, China, India, Indonesia, Vietnam, and the United States. Taken together, these partnerships will work to improve the lives of an estimated 24 million women and girls over the next three years. Experience the full interactive
- 김갑성 기자
- 2025-10-09 21:05

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-12-13_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 13일 23시 40분